Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET
Company Participants
Shai Biran - Senior Director Investor Relations
Sath Shukla - Chief Executive Officer
Esther Rajavelu - CFO and Chief Business Officer
Conference Call Participants
Louise Chen - Cantor Fitzgerald
Gavin Clark-Gartner - Evercore ISI
Ritu Baral - TD Cowen
Operator
Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode. Following the company's formal remarks we will open up the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcements on the Spero Therapeutics' website at www.sperotherapeutics.com.
At this time, I would like to turn the call over to Shai Biran, Senior Director Investor Relations. Mr. Biran, please go ahead.
Shai Biran
Thank you operator and thank you all for participating in today's conference call. This afternoon Spero Therapeutics released financial results and provided a business update for the second quarter of 2024. The press release is available on the investor page of the Spero Therapeutics website.
Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our actual clinical programs, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements.
These risks and uncertainties associated with our business and factors that could cause or contribute to such differences are described in detail in Spero Therapeutics filing with the SEC including in the risk factor section of its earnings report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC today. We also ask that you reference the cautionary statement or forward-looking statements included with the slide presentation accompanying this conference call. Participating in today's call are Sath Shukla, Chief Executive Officer, and Esther Rajavelu, Chief Financial Officer and Chief Business Officer.
Sath Shukla will begin the discussion. Please go ahead, Sath.
Sath Shukla
Thank you, Shai. Good afternoon, everyone, and thank you for joining our conference call today. I am pleased to provide an update on the ongoing progress across our portfolio of clinical stage assets.